Drug intelligence / Profile preview

ALG-097558 + remdesivir

Development stage: Unknown
Lead developer: Aligos Therapeutics
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

ALG-097558 + remdesivir is a combination therapy consisting of two antiviral drugs targeting SARS-CoV-2. ALG-097558 is a potent, pan-coronavirus protease inhibitor developed by Aligos Therapeutics that does not require ritonavir boosting. It has shown superior potency compared to nirmatrelvir (PAXLOVID) against SARS-CoV-2 and multiple resistant variants. Remdesivir is an established antiviral that works as an RNA polymerase inhibitor. This combination potentially offers a multi-mechanism approach to treating COVID-19 by targeting both viral protease and RNA polymerase.

Targets

Mpro (3C-like proteinase of SARS-CoV-2)RdRp (Coronavirus RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on ALG-097558 + remdesivir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALG-097558 + remdesivir.

Explore the full profile